Merck, Pfizer well-placed for spinoff benefits

U.S. investors have been pressuring companies to return cash to shareholders via spinoffs, and Goldman Sachs points to Merck ($MRK) and Pfizer ($PFE) as two firms that could benefit most from asset sales. Pfizer is exploring options for its animal health and nutritionals businesses. Report

Suggested Articles

With U.S. presidential and congressional campaigns in full swing, it’s not just Americans anxiously awaiting the results of the upcoming elections.

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.